Next 10 |
Halozyme Therapeutics announced that they are acquiring Antares Pharma at $5.60 per share in cash, for a total of ~$960M. The deal is expected to close in 1H of 2022. Antares develops products utilizing their drug delivery systems and has multiple royalty streams for their auto-inject...
Form 13F filings show fund managers' top merger arbitrage stocks. Top M&A stocks of the 31 funds I follow. Cerner the top merger arb stock. For further details see: Top Merger Stocks Held By Fund Managers, Mid-Q2 2022
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Value investing consists of buying unappreciated or ignored stocks at attractive prices. Value investing avoids the current stock market darlings. Lakonishok created a stir in the finance community through his research in behavioral finance. For further details see: Find...
NEW YORK, NY / ACCESSWIRE / April 21, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Tivity Health, Inc. (NASDAQ:TVT...
Thoma Bravo continued its binge of software acquisitions last week by entering into an agreement to acquire SailPoint Technologies. Kaseya, a provider of unified IT management and security software, entered into a definitive agreement to acquire Datto Holdings for $6.2 billion. Wi...
Antares Pharma (NASDAQ:ATRS) was downgraded by five firms — Truist, Ladenburg, Raymond James, Piper Sandler and H.C. Wainwright — after Halozyme Therapeutics (HALO) said on April 13 that it was acquiring Antares Pharma (ATRS) for ~$960M. Truist analyst Gregory Fraser downgr...
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab. T cells are...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...
Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...